Monoclonal Ab treatment for SARS CoV2 infection
Amanda J. Martinot (DVM, MPH, PhD) of the Tufts Vet School presented for our Monthly Science Meeting on Thursday, Jan. 28, on an article on the pre-clinical results for the Regeneron monoclonal Ab for SARS CoV-2 in hamsters and monkeys (Science), with additional discussion of the clinical trial of the same in people (NEJM).
January 29, 2021
Rima Mycynek
Veterinary pathologist Amanda J. Martinot (DVM, MPH, PhD) of the Tufts University Cummings School of Veterinary Medicine presented for our Monthly Science Meeting on Thursday, January 28, on two articles of interest in the COVID-19 pandemic: The first on the pre-clinical results for the Regeneron monoclonal Ab for SARS CoV-2 in hamsters and monkeys (Science), with additional discussion of the clinical trial of the same in people (NEJM). You can find a video of her talk below.
Dr. Martinot is an Assistant Professor in the Department of Infectious Diseases and Global Health at Cummings. She is a board-certified veterinary pathologist (anatomic) who specializes in animal models of infectious diseases of global health importance such as Tuberculosis (TB), HIV, and SARS CoV-2.
With over 10 years’ experience in TB biology, her independent research focuses on pre-clinical animal models for TB vaccine development and the basic immunology and virulence determinants underlying the TB host-pathogen interaction. As a veterinary pathologist, Dr. Martinot has expertise in animal models for infectious disease pathogenesis and drug and vaccine discovery research with a focus on non-human primate infectious disease pathology.
You can learn more about Dr. Martinot here.